# Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC

> **NCT07053215** · NA · COMPLETED · sponsor: **The First Hospital of Hebei Medical University** · enrollment: 60 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DEVICE:** Argon-Helium Cryoablation
- **DRUG:** Camrelizumab
- **DRUG:** Platinum-based doublet chemotherapy

## Key facts

- **NCT ID:** NCT07053215
- **Lead sponsor:** The First Hospital of Hebei Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07053215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07053215, "Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07053215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*